# EDGAR Filing Document

**Accession Number:** 0001187953
**File Stem:** 0001477932-25-008027
**Filing Date:** 2025-11
**Character Count:** 4836
**Document Hash:** 052ea4aea6d473194e0f29144151a967
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-25-008027.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001477932-25-008027

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001187953
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870622284
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41120
- **FILM NUMBER:** 251468352

**BUSINESS ADDRESS:**
- **STREET 1:** 211 E. OSBORN RD.
- **CITY:** PHOENIX
- **STATE:** AZ
- **ZIP:** 85012
- **BUSINESS PHONE:** 480-399-2822

**MAIL ADDRESS:**
- **STREET 1:** 211 E. OSBORN RD.
- **CITY:** PHOENIX
- **STATE:** AZ
- **ZIP:** 85012

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JOLLEY MARKETING INC
- **DATE OF NAME CHANGE:** 20020910

?xml version='1.0' encoding='ASCII'? celz_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): <u>**November 6, 2025**</u>

---

| |
|:---|
| **Creative Medical Technology Holdings, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-53500** | **87-0622284** |
| (State or other jurisdiction <br>of incorporation)  | (Commission <br>File Number)  | (I.R.S. Employer <br>Identification Number) |

---

**<u>211 E Osborn Road, Phoenix, AZ 85012</u>**

(Address of principal executive offices)

**<u>(480) 399-2822</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | CELZ | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 6, 2025, the Compensation Committee of the Board of Directors of Creative Medical Technology Holdings, Inc. (the "Company") approved the payment of bonuses to Timothy Warbington, the Company's Chief Executive Officer, and Donald Dickerson, the Company's Chief Financial Officer, in the amounts of $100,000 and $25,000, respectively.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| (d)  | <u>Exhibits</u>. |
| 104  | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

2<br>

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Creative Medical Technology Holdings, Inc.** | **Creative Medical Technology Holdings, Inc.** |
| Date: November 12, 2025 | By: | */s/ Timothy Warbington* |
|  |  | Timothy Warbington, <br>Chief Executive Officer |

---

3<br>